SCHEMBL19001002

SCHEMBL19001002

CC(C)(C)c1cnc2c(C(C)(C)C)cccc2c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.50
GABRA1 P14867 1/20 0.44
GABRB2 P47870 1/20 0.44
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALOX12 P18054 1/20 0.38
NR1H2 P55055 2/20 0.36
NR1H3 Q13133 2/20 0.36
KIF11 P52732 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PARP1 P09874 1/20 0.35
ALOX5AP P20292 2/20 0.34
FEN1 P39748 2/20 0.34
ALOX5 P09917 2/20 0.33
PTGS1 P23219 2/20 0.33
PTGS2 P35354 2/20 0.33
MMP1 P03956 1/20 0.33
MMP9 P14780 1/20 0.33
MMP13 P45452 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19000997 0.80 CCR1 (0.39) CA2GABRA1GABRB2ALDH1A1TSHR
SCHEMBL19000989 0.79 CA2 (0.36) CA2GABRA1GABRB2ALDH1A1TSHR
SCHEMBL19001126 0.79 CA2 (0.36) CA2GABRA1GABRB2ALDH1A1TSHR
SCHEMBL19422638 0.76 KDM4E (0.42) CA2GABRA1GABRB2ALDH1A1TSHR
SCHEMBL19001115 0.76 NR1H2 (0.36) CA2GABRA1GABRB2NR1H2NR1H3
SCHEMBL19000996 0.76 MMP1 (0.36) CA2GABRA1GABRB2NR1H2NR1H3
SCHEMBL19001010 0.76 NR1H2 (0.36) CA2GABRA1GABRB2NR1H2NR1H3
SCHEMBL19000953 0.76 ALOX5AP (0.38) CA2ALDH1A1NR1H2NR1H3KIF11
SCHEMBL19000995 0.76 PARP1 (0.43) CA2ALDH1A1NR1H2NR1H3PARP1
SCHEMBL13952294 0.75 KDM4E (0.46) CA2GABRA1GABRB2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938292-B2 Quinoline derivatives as SMO inhibitors GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-04-10 US disclosed
US-9938292-B2 Quinoline derivatives as SMO inhibitors GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-04-10 US disclosed
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-06-22 US disclosed
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS SMO, GLI1, SHH CA2 3659/4885GABRA1 3280/4885GABRB2 1988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.